<?xml version="1.0"?>
<!ENTITY % article SYSTEM "http://jats.nlm.nih.gov/archiving/1.2/JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.2" article-type="research-article" xml:lang="en">
      <?properties open_access?>
      <front>
        <journal-meta>
          <journal-id journal-id-type="publisher-id">13321</journal-id>
          <journal-title-group>
            <journal-title>Journal of Cheminformatics</journal-title>
            <abbrev-journal-title abbrev-type="publisher">J Cheminform</abbrev-journal-title>
          </journal-title-group>
          <issn pub-type="epub">1758-2946</issn>
          <publisher>
            <publisher-name>Springer International Publishing</publisher-name>
            <publisher-loc>Cham</publisher-loc>
          </publisher>
        </journal-meta>
        <article-meta>
          <article-id pub-id-type="publisher-id">s13321-019-0339-6</article-id>
          <article-id pub-id-type="manuscript">339</article-id>
          <article-id pub-id-type="doi">10.1186/s13321-019-0339-6</article-id>
          <article-categories>
            <subj-group subj-group-type="heading">
              <subject>Database</subject>
            </subj-group>
          </article-categories>
          <title-group>
            <article-title xml:lang="en">CSgator: an integrated web platform for compound set analysis</article-title>
          </title-group>
          <contrib-group>
            <contrib contrib-type="author" id="Au1">
              <name>
                <surname>Park</surname>
                <given-names>Sera</given-names>
              </name>
              <address>
                <email>HIDDEN</email>
              </address>
              <xref ref-type="aff" rid="Aff1">1</xref>
            </contrib>
            <contrib contrib-type="author" id="Au2">
              <name>
                <surname>Kwon</surname>
                <given-names>Yeajee</given-names>
              </name>
              <address>
                <email>HIDDEN</email>
              </address>
              <xref ref-type="aff" rid="Aff2">2</xref>
            </contrib>
            <contrib contrib-type="author" id="Au3">
              <name>
                <surname>Jung</surname>
                <given-names>Hyesoo</given-names>
              </name>
              <address>
                <email>HIDDEN</email>
              </address>
              <xref ref-type="aff" rid="Aff1">1</xref>
            </contrib>
            <contrib contrib-type="author" id="Au4">
              <name>
                <surname>Jang</surname>
                <given-names>Sukyung</given-names>
              </name>
              <address>
                <email>HIDDEN</email>
              </address>
              <xref ref-type="aff" rid="Aff1">1</xref>
            </contrib>
            <contrib contrib-type="author" id="Au5">
              <name>
                <surname>Lee</surname>
                <given-names>Haeseung</given-names>
              </name>
              <address>
                <email>HIDDEN</email>
              </address>
              <xref ref-type="aff" rid="Aff1">1</xref>
            </contrib>
            <contrib contrib-type="author" corresp="yes" id="Au6">
              <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3181-0594</contrib-id>
              <name>
                <surname>Kim</surname>
                <given-names>Wankyu</given-names>
              </name>
              <address>
                <email>HIDDEN</email>
              </address>
              <xref ref-type="aff" rid="Aff1">1</xref>
              <xref ref-type="aff" rid="Aff2">2</xref>
              <xref ref-type="corresp" rid="IDs1332101903396_cor6">f</xref>
            </contrib>
            <aff id="Aff1">
              <label>1</label>
              <institution-wrap>
                <institution-id institution-id-type="ISNI">0000 0001 2171 7754</institution-id>
                <institution-id institution-id-type="GRID">grid.255649.9</institution-id>
                <institution content-type="org-division">Ewha Research Center for Systems Biology, Department of Life Science, Division of Molecular and Life Sciences</institution>
                <institution content-type="org-name">Ewha Womans University</institution>
              </institution-wrap>
              <addr-line content-type="city">Seoul</addr-line>
              <country country="KR">Korea</country>
            </aff>
            <aff id="Aff2">
              <label>2</label>
              <institution-wrap>
                <institution content-type="org-name">KaiPharm</institution>
              </institution-wrap>
              <addr-line content-type="city">Seoul</addr-line>
              <country country="KR">Korea</country>
            </aff>
          </contrib-group>
          <author-notes>
            <corresp id="IDs1332101903396_cor6">
              <label>f</label>
              <email>HIDDEN</email>
            </corresp>
          </author-notes>
          <pub-date date-type="pub" publication-format="electronic">
            <day>4</day>
            <month>3</month>
            <year>2019</year>
          </pub-date>
          <pub-date date-type="collection" publication-format="electronic">
            <month>12</month>
            <year>2019</year>
          </pub-date>
          <volume>11</volume>
          <issue seq="17">1</issue>
          <elocation-id>17</elocation-id>
          <history>
            <date date-type="registration">
              <day>26</day>
              <month>2</month>
              <year>2019</year>
            </date>
            <date date-type="received">
              <day>25</day>
              <month>7</month>
              <year>2018</year>
            </date>
            <date date-type="accepted">
              <day>26</day>
              <month>2</month>
              <year>2019</year>
            </date>
            <date date-type="online">
              <day>4</day>
              <month>3</month>
              <year>2019</year>
            </date>
          </history>
          <permissions>
            <copyright-statement content-type="compact">© The Author(s) 2019</copyright-statement>
            <copyright-year>2019</copyright-year>
            <copyright-holder>The Author(s)</copyright-holder>
            <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
              <license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link xlink:href="http://creativecommons.org/licenses/by/4.0/" ext-link-type="uri">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link xlink:href="http://creativecommons.org/publicdomain/zero/1.0/" ext-link-type="uri">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
            </license>
          </permissions>
          <abstract xml:lang="en" id="Abs1">
            <title>Abstract</title>
            <p id="Par1">Drug discovery typically involves investigation of a set of compounds (e.g. drug screening hits) in terms of target, disease, and bioactivity. CSgator is a comprehensive analytic tool for set-wise interpretation of compounds. It has two unique analytic features of <italic>Compound Set Enrichment Analysis</italic> (CSEA) and <italic>Compound Cluster Analysis</italic> (CCA), which allows batch analysis of compound set in terms of (i) target, (ii) bioactivity, (iii) disease, and (iv) structure. CSEA and CCA present enriched profiles of targets and bioactivities in a compound set, which leads to novel insights on underlying drug mode-of-action, and potential targets. Notably, we propose a novel concept of ‘<italic>Hit Enriched Assays</italic>”, i.e. bioassays of which hits are enriched among a given set of compounds. As an example, we show its utility in revealing drug mode-of-action or identifying hidden targets for anti-lymphangiogenesis screening hits. <italic>CSgator</italic> is available at <ext-link xlink:href="http://csgator.ewha.ac.kr" ext-link-type="uri">http://csgator.ewha.ac.kr</ext-link>, and most analytic results are downloadable.</p>
          </abstract>
          <kwd-group xml:lang="en">
            <title>Keywords</title>
            <kwd>Compound set analysis</kwd>
            <kwd>Drug target</kwd>
            <kwd>Bioactivity profile</kwd>
            <kwd>Bioassay</kwd>
            <kwd>Compound network</kwd>
          </kwd-group>
          <funding-group>
            <award-group>
              <funding-source>
                <institution-wrap>
                  <institution>Ministry of Education, Science and Technology</institution>
                  <institution-id institution-id-type="doi" vocab="open-funder-registry">http://dx.doi.org/10.13039/501100004085</institution-id>
                </institution-wrap>
              </funding-source>
              <award-id award-type="FundRef grant">NRF-279 2017R1A2B4007855</award-id>
              <award-id award-type="FundRef grant">NRF-2017M3C9A5028690</award-id>
              <principal-award-recipient>
                <name>
                  <surname>Kim</surname>
                  <given-names>Wankyu</given-names>
                </name>
              </principal-award-recipient>
              <principal-award-recipient>
                <name>
                  <surname>Kim</surname>
                  <given-names>Wankyu</given-names>
                </name>
              </principal-award-recipient>
            </award-group>
            <award-group>
              <funding-source>
                <institution-wrap>
                  <institution>Institute for Information and communications Technology Promotion</institution>
                  <institution-id institution-id-type="doi" vocab="open-funder-registry">http://dx.doi.org/10.13039/501100010418</institution-id>
                </institution-wrap>
              </funding-source>
              <award-id award-type="FundRef grant">No. 2016-0-00289</award-id>
              <principal-award-recipient>
                <name>
                  <surname>Kim</surname>
                  <given-names>Wankyu</given-names>
                </name>
              </principal-award-recipient>
            </award-group>
          </funding-group>
          <custom-meta-group>
            <custom-meta>
              <meta-name>publisher-imprint-name</meta-name>
              <meta-value>Springer</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>volume-issue-count</meta-name>
              <meta-value>1</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>issue-article-count</meta-name>
              <meta-value>0</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>issue-toc-levels</meta-name>
              <meta-value>0</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>issue-pricelist-year</meta-name>
              <meta-value>2019</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>issue-copyright-holder</meta-name>
              <meta-value>The Author(s)</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>issue-copyright-year</meta-name>
              <meta-value>2019</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>article-contains-esm</meta-name>
              <meta-value>No</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>article-numbering-style</meta-name>
              <meta-value>Unnumbered</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>article-registration-date-year</meta-name>
              <meta-value>2019</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>article-registration-date-month</meta-name>
              <meta-value>2</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>article-registration-date-day</meta-name>
              <meta-value>26</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>article-toc-levels</meta-name>
              <meta-value>0</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>toc-levels</meta-name>
              <meta-value>0</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>volume-type</meta-name>
              <meta-value>Regular</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>journal-product</meta-name>
              <meta-value>ArchiveJournal</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>numbering-style</meta-name>
              <meta-value>Unnumbered</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>article-grants-type</meta-name>
              <meta-value>OpenChoice</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>metadata-grant</meta-name>
              <meta-value>OpenAccess</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>abstract-grant</meta-name>
              <meta-value>OpenAccess</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>bodypdf-grant</meta-name>
              <meta-value>OpenAccess</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>bodyhtml-grant</meta-name>
              <meta-value>OpenAccess</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>bibliography-grant</meta-name>
              <meta-value>OpenAccess</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>esm-grant</meta-name>
              <meta-value>OpenAccess</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>online-first</meta-name>
              <meta-value>false</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>pdf-file-reference</meta-name>
              <meta-value>BodyRef/PDF/13321_2019_Article_339.pdf</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>target-type</meta-name>
              <meta-value>OnlinePDF</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>issue-type</meta-name>
              <meta-value>Regular</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>article-type</meta-name>
              <meta-value>OriginalPaper</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>journal-subject-primary</meta-name>
              <meta-value>Chemistry</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>journal-subject-secondary</meta-name>
              <meta-value>Computer Applications in Chemistry</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>journal-subject-secondary</meta-name>
              <meta-value>Documentation and Information in Chemistry</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>journal-subject-secondary</meta-name>
              <meta-value>Theoretical and Computational Chemistry</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>journal-subject-secondary</meta-name>
              <meta-value>Computational Biology/Bioinformatics</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>journal-subject-collection</meta-name>
              <meta-value>Chemistry and Materials Science</meta-value>
            </custom-meta>
            <custom-meta>
              <meta-name>open-access</meta-name>
              <meta-value>true</meta-value>
            </custom-meta>
          </custom-meta-group>
        </article-meta>
      </front>
      <body>
        <sec id="Sec1">
          <title>Introduction</title>
          <p id="Par26">During the early phase of drug discovery, it is common to identify multiple hit compounds by high-throughput screening (HTS) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. It is critical to survey their known targets, activities, and disease indications to avoid potential toxicity or side-effects, to understand structure-activity relations (SAR), and to direct medicinal chemistry for lead generation. Active exploitation of polypharmacology (e.g. dual inhibitors) or drug combination has also been considered as a viable strategy to overcome drug resistance or tumor heterogeneity in cancer therapy [<xref ref-type="bibr" rid="CR3">3</xref>]. Although scientists have access to many chemogenomic databases, they are not comprehensive enough individually, nor suitable or convenient for batch analyses of a compound set [<xref ref-type="bibr" rid="CR4">4</xref>–<xref ref-type="bibr" rid="CR8">8</xref>]. Recent explosion of bioassay datasets (e.g. PubChem and ChEMBL [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]) made rich information available on diverse aspects of bioactivities, but such data have been used only limitedly in drug discovery. Several integrated compound-target DBs are available, but are limited in analytic functions [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. There were several works on predictive analyses based on bioactivity profiles or fingerprints, most of which did not fully exploited bioactivity data available [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>], or were difficult to use for researchers without programming skills [<xref ref-type="bibr" rid="CR15">15</xref>].</p>
          <p id="Par27">Here, we developed CSgator (Compound Set navigator), a web platform that provides a comprehensive interpretation of compound set. It is equipped with unique analytic features of <italic>Compound Set Enrichment Analysis</italic> (CSEA) and <italic>Compound Cluster Analysis</italic> (CCA). Particularly, we provide unique analytic functions such as <italic>HEA</italic> analysis (<italic>Hit Enrichment Analysis</italic>) that provide novel insights or clues on drug mode-of-action, or underlying targets of phenotypic screening hits (e.g. lymphangiogenesis) as described in the following sections with an example case.</p>
        </sec>
        <sec id="Sec2" sec-type="materials|methods">
          <title>Materials and methods</title>
          <sec id="Sec3">
            <title>Standardization of compound IDs and gene names</title>
            <p id="Par28">In order to avoid redundancy, CSgator amassed a consolidated set of compounds from public chemical database such as PubChem, ChEMBL, ChEBI, and DrugBank [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. We then merged different isotopic, (un)charged, and (de)protonated forms of the same molecule into a single compound ID. For example, lovastatin, a HMG-CoA reductase inhibitor falls into 62 PubChem CIDs, all of which would show essentially the same or highly similar biological activity. All the compounds were mapped to a unified compound ID based on IUPAC InChIKey (IUPAC International Chemical Identifier Key) using Open Babel v.2.3 [<xref ref-type="bibr" rid="CR17">17</xref>] by converting SMILES or MOL format to InChIKey strings as well as by manual mapping of compound names where necessary. Gene IDs were standardized using the gene names given by UniProtKB and NCBI Gene [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>].</p>
          </sec>
          <sec id="Sec4">
            <title>Collection of compound-target interaction data</title>
            <p id="Par29">We collected compound-target interaction data from 15 public databases: CTD, DCDB, DrugBank, MATADOR, TTD, BindingDB, ChEMBL, KiDB, KEGG Drug, PharmGKB, IUPHAR, Binding MOAD, DGIdb, GLASS, STITCH [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR6">6</xref>–<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR20">20</xref>–<xref ref-type="bibr" rid="CR29">29</xref>]. After ID standardization of compounds and genes, a total of > 3 mil. compound-target interactions are collected (Table <xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption xml:lang="en"><p>Compound-target interaction data from 15 public databases</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>Source name</p></th><th align="left"><p># interactions</p></th></tr></thead><tbody><tr><td align="left"><p>BindingDB</p></td><td char="." align="char"><p>1,078,520</p></td></tr><tr><td align="left"><p>Binding MOAD</p></td><td char="." align="char"><p>15,320</p></td></tr><tr><td align="left"><p>Comparative Toxicogenomics Database</p></td><td char="." align="char"><p>77,327</p></td></tr><tr><td align="left"><p>ChEMBL v.21</p></td><td char="." align="char"><p>512,341</p></td></tr><tr><td align="left"><p>DCDB</p></td><td char="." align="char"><p>1902</p></td></tr><tr><td align="left"><p>DGIdb</p></td><td char="." align="char"><p>16,852</p></td></tr><tr><td align="left"><p>DrugBank</p></td><td char="." align="char"><p>12,501</p></td></tr><tr><td align="left"><p>IUPHAR</p></td><td char="." align="char"><p>12,429</p></td></tr><tr><td align="left"><p>KEGG Drug</p></td><td char="." align="char"><p>9787</p></td></tr><tr><td align="left"><p>KiDB</p></td><td char="." align="char"><p>20,610</p></td></tr><tr><td align="left"><p>MATADOR</p></td><td char="." align="char"><p>1163</p></td></tr><tr><td align="left"><p>PharmGKB</p></td><td char="." align="char"><p>3606</p></td></tr><tr><td align="left"><p>Therapeutic Targets Database</p></td><td char="." align="char"><p>45,901</p></td></tr><tr><td align="left"><p>GLASS</p></td><td char="." align="char"><p>460,881</p></td></tr><tr><td align="left"><p>STITCH v.5<sup>a</sup></p></td><td char="." align="char"><p>788,024</p></td></tr><tr><td align="left"><p>Total</p></td><td char="." align="char"><p>3,057,164</p></td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>STITCH provides scores for protein–chemical interactions, we filtered that interactions on two conditions: experimental score ≥ 700 and database score ≥ 700</p></table-wrap-foot></table-wrap></p>
          </sec>
          <sec id="Sec5">
            <title>Classification of targets and diseases</title>
            <p id="Par30">Compounds and targets were classified by four different annotations: (I) Protein family classes by ChEMBL version 21, (II) Gene Ontology (GO) terms on Biological Process (BP) [<xref ref-type="bibr" rid="CR30">30</xref>], (III) Disease Ontology (DO) terms that cross reference with MeSH (Medical Subject Headings), ICD (International Classification of Diseases), NCI’s thesaurus, SNOMED (Systemized Nomenclature of Medicine) and OMIM [<xref ref-type="bibr" rid="CR31">31</xref>], and (IV) MeSH Disease term provided by NLM (U.S. National Library of Medicine) [<xref ref-type="bibr" rid="CR32">32</xref>].</p>
          </sec>
          <sec id="Sec6">
            <title>Bioassay data from PubChem Bioassay and ChEMBL</title>
            <p id="Par31">Bioassay data include information for diverse aspects of compound bioactivities. We collected over 1.2 mil. bioassay dataset for > 2 mil. compounds from PubChem Bioassay and ChEMBL [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Some of the bioassay dataset were not in a standardized format and required further processing such as ordering compounds by activity, assignment of hit/non-hit compounds, and target ID standardization for targeted bioassays. We assigned compounds as hit by applying one of the three criteria. First, PubChem Bioassay and ChEMBL provide active/inactive information for ~ 22% of the total assays (~ 270,000 bioassays), and accordingly, we took the information to assign hit or non-hit compounds. For the remaining bioassays without active/inactive annotation, the cut-off of Z score ≥ 2 or the top 1% were applied as the second and the third criteria, and took the union of the resulting compound sets as hits. Because only a small fraction of the assays were annotated to a specific target, we also performed a manual curation to assign bioassays to a specific target whenever target information is available in the assay title or description. As a result, ~ 10.3% of the total assays were assigned to a specific target.</p>
          </sec>
          <sec id="Sec7">
            <title>Generation of structural properties</title>
            <p id="Par32">We calculated structural and physicochemical properties of all the compounds, which can be exploited for characterization or filtering of a compound set using Open Babel toolbox [<xref ref-type="bibr" rid="CR17">17</xref>]. The physicochemical properties were calculated such as molecular weight, FP2 fingerprint, logP (Partition coefficient), topological polar surface area (TPSA), and hydrogen bond donor and acceptor. Additionally, we generate predictors for lead-likeness, i.e. Lipinski’s the rule, and QED (quantitative estimation of drug-likeness) by Gregory Gerebtzoff (Roche, Switerland) implemented in Silico-it package [<xref ref-type="bibr" rid="CR33">33</xref>].</p>
          </sec>
        </sec>
        <sec id="Sec8">
          <title>Utility and discussion</title>
          <sec id="Sec9">
            <title>System overview</title>
            <p id="Par33">CSgator includes information on ~ 90 million compounds after merging redundant entries, > 6 million compound-target relations from 15 public databases (Table <xref rid="Tab1" ref-type="table">1</xref>), ~ 1.6 million compound-disease associations, and > 230 million bioactivity points collected from > 1.2 million bioassay data set. Whenever available, compounds and targets were annotated by protein family, functional annotation by Gene Ontology [<xref ref-type="bibr" rid="CR30">30</xref>], and disease categories by Disease Ontology and MeSH [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. As described in the following sections, these annotations are crucial to interpret the characteristics of input compound set, and provide novel clues on drug mode-of-action, and will be expanded as more information accumulate. Data sources and current statistics are listed in Table <xref rid="Tab2" ref-type="table">2</xref>. These data may be available elsewhere, but CSgator is unique for its comprehensiveness, clean mapping between different resources, and full data accessibility. <table-wrap id="Tab2"><label>Table 2</label><caption xml:lang="en"><p>Data sources and statistics collected in CSgator</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" /><th align="left"><p>Number of entries</p></th><th align="left"><p>Number of compounds</p></th><th align="left"><p>Sources</p></th><th align="left"><p>Number of relations</p></th><th align="left"><p>Standard ID</p></th></tr></thead><tbody><tr><td align="left" colspan="6"><p><italic>Compound database</italic></p></td></tr><tr><td align="left"><p>Compound</p></td><td align="left"><p>–</p></td><td char="." align="char"><p>89,602,599</p></td><td align="left"><p>PubChem, ChEMBL, ChEBI, DrugBank</p></td><td align="left"><p>–</p></td><td align="left"><p>InChIKey</p></td></tr><tr><td align="left" colspan="6"><p><italic>Compound</italic>-<italic>target &amp; disease &amp; bioassay</italic></p></td></tr><tr><td align="left"><p>Target</p></td><td align="left"><p>252,498</p></td><td char="." align="char"><p>852,375</p></td><td align="left"><p>15 Public DBs</p></td><td align="left"><p>6,027,120</p></td><td align="left"><p>Entrez Gene ID &amp; UniProtKB</p></td></tr><tr><td align="left"><p>Disease</p></td><td align="left"><p>5680</p></td><td char="." align="char"><p>10,975</p></td><td align="left"><p>CTD</p></td><td align="left"><p>1,575,457</p></td><td align="left"><p>MeSH &amp; OMIM</p></td></tr><tr><td align="left"><p>Bioassay</p></td><td align="left"><p>1,218,658</p></td><td char="." align="char"><p>2,253,835</p></td><td align="left"><p>PubChem, ChEMBL</p></td><td align="left"><p>229,842,265</p></td><td align="left"><p>PubChem AID &amp; ChEMBL</p></td></tr><tr><td align="left" colspan="6"><p><italic>Classification</italic></p></td></tr><tr><td align="left"><p>Protein family</p></td><td align="left"><p>575</p></td><td char="." align="char"><p>833,590</p></td><td align="left"><p>ChEMBL 21</p></td><td align="left"><p>1,691,879</p></td><td align="left"><p>ChEMBL protein class</p></td></tr><tr><td align="left"><p>GO term</p></td><td align="left"><p>19,234</p></td><td char="." align="char"><p>851,359</p></td><td align="left"><p>Gene Ontology</p></td><td align="left"><p>68,331,986</p></td><td align="left"><p>GO term</p></td></tr><tr><td align="left"><p>Disease ontology</p></td><td align="left"><p>1824</p></td><td char="." align="char"><p>5429</p></td><td align="left"><p>Disease Ontology</p></td><td align="left"><p>46,053</p></td><td align="left"><p>DO term</p></td></tr><tr><td align="left"><p>MeSH disease</p></td><td align="left"><p>6351</p></td><td char="." align="char"><p>6909</p></td><td align="left"><p>NIH</p></td><td align="left"><p>143,277</p></td><td align="left"><p>MeSH</p></td></tr><tr><td align="left"><p>Approval status</p></td><td align="left"><p>9</p></td><td char="." align="char"><p>3765</p></td><td align="left"><p>DrugBank</p><p>ChEMBL</p><p>NCGC</p></td><td align="left"><p>12,820</p></td><td align="left"><p>InChIKey</p></td></tr></tbody></table></table-wrap></p>
            <p id="Par34">The analytic workflow of CSgator consists of three steps of (i) generation of input compound set, (ii) tabular listing of annotations for the input compound set, and (iii) compound set analysis step as depicted in Fig. <xref rid="Fig1" ref-type="fig">1</xref>. First, input compound set can be generated in three different ways: (a) by <italic>Compound ID Search</italic> using SMILES, InChI, InChIKey, CAS Registry Number, and other IDs including PubChem, ChEMBL, ChEBI, and DrugBank, (b) by <italic>Compound Structure Search</italic> for compounds with specific scaffolds or by structural similarity, and (c) by <italic>Compound Set Selection</italic>, where the precompiled compound set is selected. Precompiled compound sets were built in various ways, e.g. by target or target family, approval status by FDA and other countries, and disease indication. Notably, users can also freely generate a new compound set by applying <italic>Set Operator</italic> to precompiled or input compound sets, and by filtering compounds based on physicochemical properties. Second, CSgator internally gathers all the annotations of input compounds that are grouped into four categories: (i) target, (ii) bioassay, (iii) disease, and (iv) structure. All the annotations are listed and downloadable in a tabular format. Third, user can investigate collective information of a compound set, which is not available in other related databases. The two unique analyses in CSgator are <italic>CSEA (Compound Set Enrichment Analysis)</italic> and <italic>CCA (Compound Cluster Analysis)</italic>, which will be further explained in the following sections.<fig id="Fig1"><label>Fig. 1</label><caption xml:lang="en"><p>System overview of CSgator web platform. <bold>a</bold><italic>Input Compound Set</italic> generated by user or selected among the predefined sets. It can be also created by applying various filters, and combining multiple sets using <italic>Set Operator</italic> such as union or intersection. <bold>b</bold> Comprehensive annotations of the input compound set are listed in four categories: <italic>target</italic>, <italic>bioactivity (bioassay)</italic>, <italic>disease</italic>, and <italic>structure</italic>. <bold>c</bold> CSgator provides unique analyses. i.e. Compound Set Enrichment Analysis (CSEA) and Compound Cluster Analysis (CCA), of which details are described in the main text</p></caption><graphic specific-use="HTML" mime-subtype="PNG" xlink:href="MediaObjects/13321_2019_339_Fig1_HTML.png" /></fig></p>
          </sec>
          <sec id="Sec10">
            <title>Compound Set Enrichment Analysis (CSEA)</title>
            <p id="Par35">Similarly to <italic>Gene Set Enrichment Analysis (GSEA</italic> [<xref ref-type="bibr" rid="CR34">34</xref>]), <italic>Compound Set Enrichment Analysis (CSEA)</italic> refers to investigating enriched annotations for a compound set. Varin et al. [<xref ref-type="bibr" rid="CR35">35</xref>] applied CSEA to identify active scaffolds enriched in primary screening data. We extend CSEA even further to annotations on target, disease, and bioassay hits. Particularly, we propose a novel concept of <italic>Hit Enriched Assays (HEAs)</italic> as bioassays of which hits are enriched among the compound set of interest. Since bioassays generally have intended targets and biological processes, HEAs can provide non-obvious links to the underlying targets and drug mode-of-actions enriched in the input compound set such as phenotypic screening hits. Similarly, it also shows enriched targets or diseases in a tree format, i.e. Target Enrichment Tree (TET), and Disease Enrichment Tree (DET). The degree of enrichment, or <italic>Enrichment Score (ES)</italic> is calculated as log likelihood ratio (LLR) for HEAs, and odds ratio for TET and DET.<disp-formula id="Equa"><alternatives><mml:math display="block" id="Equa_Math"><mml:mrow><mml:mtable><mml:mtr><mml:mtd /><mml:mtd columnalign="left"><mml:mrow><mml:mi>E</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi mathvariant="italic">HEA</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>L</mml:mi><mml:mi>L</mml:mi><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mo>log</mml:mo><mml:mn>2</mml:mn></mml:msub><mml:mfenced close=")" open="(" separators=""><mml:mfrac><mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo><mml:mi>Q</mml:mi><mml:mo>∩</mml:mo><mml:mi>H</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:mo stretchy="false">/</mml:mo><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:msup><mml:mi>Q</mml:mi><mml:mi>C</mml:mi></mml:msup><mml:mrow><mml:mo>∩</mml:mo><mml:mi>H</mml:mi><mml:mo stretchy="false">|</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo><mml:mi>Q</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:mo stretchy="false">/</mml:mo><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:msup><mml:mi>Q</mml:mi><mml:mi>C</mml:mi></mml:msup><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mfenced></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:mrow /></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mi>E</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>E</mml:mi><mml:mi>T</mml:mi><mml:mspace width="0.166667em" /><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mspace width="0.166667em" /><mml:mi>D</mml:mi><mml:mi>E</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>O</mml:mi><mml:mi>d</mml:mi><mml:mi>d</mml:mi><mml:mi>s</mml:mi><mml:mspace width="0.166667em" /><mml:mi>R</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mo>log</mml:mo><mml:mn>2</mml:mn></mml:msub><mml:mfenced close=")" open="(" separators=""><mml:mfrac><mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo><mml:mi>Q</mml:mi><mml:mo>⊗</mml:mo><mml:mi>H</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:mo stretchy="false">/</mml:mo><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:msup><mml:mi>Q</mml:mi><mml:mi>C</mml:mi></mml:msup><mml:mrow><mml:mo>⊗</mml:mo><mml:mi>H</mml:mi><mml:mo stretchy="false">|</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo><mml:mi>Q</mml:mi><mml:mo>⊗</mml:mo></mml:mrow><mml:msup><mml:mi>H</mml:mi><mml:mi>C</mml:mi></mml:msup><mml:mrow><mml:mo stretchy="false">|</mml:mo><mml:mo stretchy="false">/</mml:mo><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:msup><mml:mi>Q</mml:mi><mml:mi>C</mml:mi></mml:msup><mml:mo>⊗</mml:mo><mml:msup><mml:mi>H</mml:mi><mml:mi>C</mml:mi></mml:msup><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mfenced></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:mrow /></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mo stretchy="false">|</mml:mo><mml:mi>Q</mml:mi><mml:mo>⊗</mml:mo><mml:mi>H</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:mo>:</mml:mo><mml:mi>T</mml:mi><mml:mi>h</mml:mi><mml:mi>e</mml:mi><mml:mspace width="0.166667em" /><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mi>b</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mspace width="0.166667em" /><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mspace width="0.166667em" /><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>s</mml:mi><mml:mspace width="0.166667em" /><mml:mi>b</mml:mi><mml:mi>e</mml:mi><mml:mi>t</mml:mi><mml:mi>w</mml:mi><mml:mi>e</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mspace width="0.166667em" /><mml:mi>Q</mml:mi><mml:mspace width="0.166667em" /><mml:mo stretchy="false">(</mml:mo><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>m</mml:mi><mml:mi>p</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi><mml:mspace width="0.166667em" /><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mspace width="0.166667em" /><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi><mml:mspace width="0.166667em" /><mml:mi>H</mml:mi><mml:mspace width="0.166667em" /><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>r</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mi>t</mml:mi><mml:mspace width="0.166667em" /><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mspace width="0.166667em" /><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:mrow /></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><tex-math id="Equa_TeX">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym}
				\usepackage{amsfonts}
				\usepackage{amssymb}
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} &amp; ES_{HEA} = LLR = \log_{2} \left( {\frac{{|Q \cap H|/|Q^{C} \cap H|}}{{|Q|/|Q^{C} |}}} \right) \\ &amp; ES_{TET\,or\,DET} = Odds\,Ratio = \log_{2} \left( {\frac{{|Q \otimes H|/|Q^{C} \otimes H|}}{{|Q \otimes H^{C} |/|Q^{C} \otimes H^{C} |}}} \right) \\ &amp; |Q \otimes H|:The\,number\,of\,interactions\,between\,Q\,(compound\,set)\,and\,H\,(target\,or\,disease), \\ \end{aligned}$$\end{document}</tex-math><graphic position="anchor" xlink:href="13321_2019_339_Article_Equa.gif" /></alternatives></disp-formula>where Q is the input or query compounds, and Q<sup>C</sup> is the compounds that do not belong to Q. H is the compounds of interest, e.g. hit compounds for HEA, ligands for a target or target family for TET, and compounds related to a disease for DET analysis. In calculating ES for TET (or DET), we assume compounds not in the query Q<sup>C</sup> do NOT interact with the target or target family (or disease) although more interactions may exist, but not yet discovered in any test. These missing information may skew the results of TET (or DET), which should be cautiously interpreted. Later, we show an example case of CSEA in interpreting anti-lymphangiogenesis screening hits in the ‘Case Study’ section below.</p>
          </sec>
          <sec id="Sec11">
            <title>Compound Cluster Analysis (CCA)</title>
            <p id="Par36">Structurally similar compounds tend to share the same or structurally similar targets [<xref ref-type="bibr" rid="CR36">36</xref>]. With the purpose to investigate this aspect, CSgator first generates <italic>Compound Clusters</italic> (CCs) of structurally similar subgroups by k-means clustering. It then shows <italic>Compound Cluster Network</italic> (CC-Network), showing connections among the compound clusters with target family or disease classes. Similarly to CSEA, the degree of enrichment for each CC is also calculated as odd ratio, where R represent the compounds of each cluster (CC), and R<sup>C</sup> is the all other compounds in the database. Therefore, CC-Network provides information on how a structurally similar cluster of compounds (CC) would be significantly associated to a specific target family or disease class compared to all other compounds as background.<disp-formula id="Equb"><alternatives><mml:math display="block" id="Equb_Math"><mml:mrow><mml:mtable><mml:mtr><mml:mtd /><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mtext>ES</mml:mtext><mml:mrow><mml:mi mathvariant="italic">CCA</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mtext>Odd</mml:mtext><mml:mspace width="0.166667em" /><mml:mtext>Ratio</mml:mtext><mml:mo>=</mml:mo><mml:msub><mml:mo>log</mml:mo><mml:mn>2</mml:mn></mml:msub><mml:mfenced close=")" open="(" separators=""><mml:mfrac><mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo><mml:mi>R</mml:mi><mml:mo>⊗</mml:mo><mml:mi>H</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:mo stretchy="false">/</mml:mo><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:msup><mml:mi>R</mml:mi><mml:mi>C</mml:mi></mml:msup><mml:mrow><mml:mo>⊗</mml:mo><mml:mi>H</mml:mi><mml:mo stretchy="false">|</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo><mml:mi>R</mml:mi><mml:mo>⊗</mml:mo></mml:mrow><mml:msup><mml:mi>H</mml:mi><mml:mi>C</mml:mi></mml:msup><mml:mrow><mml:mo stretchy="false">|</mml:mo><mml:mo stretchy="false">/</mml:mo><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:msup><mml:mi>R</mml:mi><mml:mi>C</mml:mi></mml:msup><mml:mo>⊗</mml:mo><mml:msup><mml:mi>H</mml:mi><mml:mi>C</mml:mi></mml:msup><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mfenced></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:mrow /></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mfenced close="|" open="|" separators=""><mml:mrow><mml:mi>R</mml:mi><mml:mo>⊗</mml:mo><mml:mi>H</mml:mi></mml:mrow></mml:mfenced><mml:mo>:</mml:mo><mml:mi>T</mml:mi><mml:mi>h</mml:mi><mml:mi>e</mml:mi><mml:mspace width="0.166667em" /><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mi>b</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mspace width="0.166667em" /><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mspace width="0.166667em" /><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>s</mml:mi><mml:mspace width="0.166667em" /><mml:mi>b</mml:mi><mml:mi>e</mml:mi><mml:mi>t</mml:mi><mml:mi>w</mml:mi><mml:mi>e</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mspace width="0.166667em" /><mml:mi>R</mml:mi><mml:mspace width="0.166667em" /><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>m</mml:mi><mml:mi>p</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi><mml:mspace width="0.166667em" /><mml:mi>c</mml:mi><mml:mi>l</mml:mi><mml:mi>u</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mspace width="0.166667em" /><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi><mml:mspace width="0.166667em" /><mml:mi>H</mml:mi><mml:mspace width="0.166667em" /><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>r</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mi>t</mml:mi><mml:mspace width="0.166667em" /><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mspace width="0.166667em" /><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:mrow /></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><tex-math id="Equb_TeX">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym}
				\usepackage{amsfonts}
				\usepackage{amssymb}
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} &amp; {\text{ES}}_{CCA} = {\text{Odd}}\,{\text{Ratio}} = \log_{2} \left( {\frac{{|R \otimes H|/|R^{C} \otimes H|}}{{|R \otimes H^{C} |/|R^{C} \otimes H^{C} |}}} \right) \\ &amp; \left| {R \otimes H} \right|:The\,number\,of\,interactions\,between\,R\,(compound\,cluster)\,and\,H\,(target\,or\,disease) \\ \end{aligned}$$\end{document}</tex-math><graphic position="anchor" xlink:href="13321_2019_339_Article_Equb.gif" /></alternatives></disp-formula></p>
          </sec>
          <sec id="Sec12">
            <title>A case study on interpreting phenotypic screening hits</title>
            <p id="Par37">Here, we show the utility of the two main analytic functions in CSgator using a case study in interpreting phenotypic screening hits. We took the high-content phenotype-based assay data for screening inhibitors of lymphangiogenesis [<xref ref-type="bibr" rid="CR37">37</xref>]. Schulz et al. screened FDA approved 1280 drugs (Library of Pharmacologically Active Compounds or LOPAC library from Sigma), resulting in identifying 31 hits (hit rate of 2.4%). The 31 hits were mapped to 40 unique compound IDs in CSgator. But this screening dataset alone does not provide information on the underlying targets or drug mode-of-action. With the 40 compounds as an input set, we performed CSEA and CCA analyses implemented in CSgator as described in the following section.</p>
            <sec id="Sec13">
              <title>CSEA (Compound Set Enrichment Analysis)</title>
              <p id="Par38">CSEA investigates enriched annotations in terms of target, disease, and bioactivities. In HEA analysis, CSgator listed 146 bioassays, where the 40 input compounds were significantly enriched as hits. We took the list of HEAs that have explicit information on their intended targets with high enrichment score (ES > 5) as listed in Table <xref rid="Tab3" ref-type="table">3</xref>. The targets of the top ranked HEAs include many genes that were known to be involved in lymphangiogenesis. The top ranking HEA (ES = 9.75) screened for RGS4 (Regulator of G-protein signaling 4) inhibitors. Indeed, RGS4 plays a key role in regulating tubulogenesis including lymphangiogenesis by antagonizing MAPK and VEGF signaling [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. The third and fifth HEA targeted mTOR (ES = 7.12), which generally known to control lymphangiogenesis [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. Thrombopoietin (TPO) is the regulator of thrombocyte production, and recent studies provide evidence for the critical role of the thrombocytes in lymphangiogenesis in human malignant tumors [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. A bioassay targeting TPO was ranked at the top 7th with ES = 6.21. Vascular endothelial growth factor D (VEGF-D) has been implicated in the key role of lymphangiogenesis. TNF-α induces AP-1 binding to the VEGF-D promoter, and increase VEGF-D expression through TNF-α/ERK1/2/AP-1 pathway, which promotes lymphangiogenesis and lymphatic metastasis [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. The 10th HEA (ES = 5.85) targeted AP1 signaling. In summary, five out of the top 10 HEAs provided direct links to the known genes associated to lymphangiogenesis. Accordingly, other targets of high ranking HEAs may be also involved in lymphangiogenesis, such as GMNN, ATAD5, ATXN2, and FEN1 (Table <xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption xml:lang="en"><p>HEAs (Hit Enriched Assays) from lymphangiogenesis hits</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>Rank</p></th><th align="left"><p>Assay title</p></th><th align="left"><p>Target</p><p>gene</p></th><th align="left"><p>Enrichment score of HEA</p></th><th align="left"><p>Number of hit/assayed compounds</p></th><th align="left"><p>FDR-adjusted <italic>p</italic> value</p></th><th align="left"><p>PubChem AID</p><p>(year)</p></th><th align="left"><p>Reference</p></th></tr></thead><tbody><tr><td align="left"><p>1</p></td><td align="left"><p>Inhibitors of regulator of G protein signaling (RGS) 4</p></td><td align="left"><p>RGS4</p></td><td align="left"><p>9.63</p></td><td align="left"><p>152/390,220</p></td><td align="left"><p>3.40E−16</p></td><td align="left"><p>504,845 (2011)</p></td><td align="left"><p>[<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]</p></td></tr><tr><td align="left"><p>2</p></td><td align="left"><p>Validation screen for inhibitors of Lassa infection</p></td><td align="left"><p>–</p></td><td align="left"><p>7.18</p></td><td align="left"><p>54/1279</p></td><td align="left"><p>3.04E−13</p></td><td align="left"><p>463,096 (2010)</p></td><td align="left" /></tr><tr><td align="left"><p>3</p></td><td align="left"><p>High content imaging cell-Based qHTS for inhibitors of the mTORC1 signaling pathway in MEF (Tsc2-/-, p53-/-) cells</p></td><td align="left"><p>MTOR</p></td><td align="left"><p>7.12</p></td><td align="left"><p>23/1280</p></td><td align="left"><p>8.03E−09</p></td><td align="left"><p>2666 (2010)</p></td><td align="left"><p>[<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]</p></td></tr><tr><td align="left"><p>4</p></td><td align="left"><p>Validation screen for small molecules that induce DNA re-replication in MCF 10A normal breast cells</p></td><td align="left"><p>GMNN</p></td><td align="left"><p>6.77</p></td><td align="left"><p>71/1280</p></td><td align="left"><p>4.61E−11</p></td><td align="left"><p>463,097 (2010)</p></td><td align="left" /></tr><tr><td align="left"><p>5</p></td><td align="left"><p>High content imaging cell-based qHTS for inhibitors of the mTORC1 signaling pathway in MEF cells</p></td><td align="left"><p>MTOR</p></td><td align="left"><p>6.35</p></td><td align="left"><p>52/1280</p></td><td align="left"><p>1.85E−10</p></td><td align="left"><p>2667 (2010)</p></td><td align="left"><p>[<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]</p></td></tr><tr><td align="left"><p>6</p></td><td align="left"><p>Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1</p></td><td align="left"><p>ATAD5</p></td><td align="left"><p>6.22</p></td><td align="left"><p>79/1280</p></td><td align="left"><p>3.78E−10</p></td><td align="left"><p>493,107 (2011)</p></td><td align="left" /></tr><tr><td align="left"><p>7</p></td><td align="left"><p>qHTS assay for identification of small molecule antagonists for thrombopoietin (TPO) signaling pathway</p></td><td align="left"><p>THPO</p></td><td align="left"><p>6.21</p></td><td align="left"><p>122/1277</p></td><td align="left"><p>1.11E−08</p></td><td align="left"><p>918 (2010)</p></td><td align="left"><p>[<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]</p></td></tr><tr><td align="left"><p>8</p></td><td align="left"><p>qHTS for inhibitors of ATXN expression: validation</p></td><td align="left"><p>ATXN2</p></td><td align="left"><p>5.94</p></td><td align="left"><p>73/1280</p></td><td align="left"><p>2.67E−07</p></td><td align="left"><p>588,378 (2011)</p></td><td align="left" /></tr><tr><td align="left"><p>9</p></td><td align="left"><p>qHTS assay for the inhibitors of human flap endonuclease 1 (FEN1)</p></td><td align="left"><p>FEN1</p></td><td align="left"><p>5.87</p></td><td align="left"><p>1368/391,275</p></td><td align="left"><p>2.04E−07</p></td><td align="left"><p>588,795 (2011)</p></td><td align="left" /></tr><tr><td align="left"><p>10</p></td><td align="left"><p>AP1 signaling pathway</p></td><td align="left"><p>AP1</p></td><td align="left"><p>5.85</p></td><td align="left"><p>55/10,692</p></td><td align="left"><p>4.90E−5</p></td><td align="left"><p>357 (2006)</p></td><td align="left"><p>[<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]</p></td></tr></tbody></table></table-wrap></p>
              <p id="Par39">Similarly, we performed Target Enrichment Tree (TET) analysis to get useful clues to underlying targets of phenotypic screening assays. CSgator listed target protein families prioritized by enrichment score (Table <xref rid="Tab4" ref-type="table">4</xref>). The top ranked target family was calcium-activated chloride channel family (ES = 5.90), of which key role was reported in lymph node remodeling by induction of lymphangiogenesis [<xref ref-type="bibr" rid="CR46">46</xref>]. Among the 40 input compounds, only 2 compounds are known to interact with the targets of the family members in our dataset. It demonstrates the current lack of enough compound-target data even after the integration of 15 publicly available datasets. Therefore, the utility of TET or DET analysis may be limited at the moment compared to HEA analysis. In spite of this limitation, it showed significant enrichment (FDR-adjusted <italic>p</italic> value = 0.00431). We were able to identify other target families potentially associated to lymphangiogenesis. The families related to cytochrome P450 were found frequently within the top 10 ranks (five out of the ten families). It may be associated that oxygen released by oxidoreduction in lymph tissue causes expansion of lymphatic vessels [<xref ref-type="bibr" rid="CR47">47</xref>]. If we use a larger input set and collect more compound-target dataset, TET analysis may become more useful with better statistical power.<table-wrap id="Tab4"><label>Table 4</label><caption xml:lang="en"><p>Target enrichment tree results from lymphangiogenesis hits</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>Rank</p></th><th align="left"><p>Target family</p></th><th align="left"><p>Target</p></th><th align="left"><p><inline-formula id="IEq1"><alternatives><mml:math id="IEq1_Math"><mml:mrow><mml:mi>Q</mml:mi><mml:mo>⊗</mml:mo><mml:mi>H</mml:mi></mml:mrow></mml:math><tex-math id="IEq1_TeX">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym}
				\usepackage{amsfonts}
				\usepackage{amssymb}
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$Q \otimes H$$\end{document}</tex-math><inline-graphic xlink:href="13321_2019_339_Article_IEq1.gif" /></alternatives></inline-formula></p></th><th align="left"><p>Enrichment score</p></th><th align="left"><p>FDR adjusted <italic>p</italic> value</p></th></tr></thead><tbody><tr><td align="left"><p>1</p></td><td align="left"><p>CA ACT CL (calcium-activated chloride channel)</p></td><td align="left"><p>ANO1</p></td><td align="left"><p>2</p></td><td align="left"><p>5.90</p></td><td align="left"><p>4.31E−03</p></td></tr><tr><td align="left"><p>3</p></td><td align="left"><p>CYP_3A2 (cytochrome P450 3A2)</p></td><td align="left"><p>Cyp3a2 (Tax ID: 10116)</p></td><td align="left"><p>2</p></td><td align="left"><p>5.30</p></td><td align="left"><p>8.34E−03</p></td></tr><tr><td align="left"><p>4</p></td><td align="left"><p>SLC47 (SLC47 family of multidrug and toxin extrusion transporters)</p></td><td align="left"><p>SLC47A1</p></td><td align="left"><p>2</p></td><td align="left"><p>4.48</p></td><td align="left"><p>2.21E−02</p></td></tr><tr><td align="left"><p>5</p></td><td align="left"><p>Structural (structural protein)</p></td><td align="left"><p>COL1A2</p></td><td align="left"><p>38</p></td><td align="left"><p>4.07</p></td><td align="left"><p>6.33E−31</p></td></tr><tr><td align="left"><p>6</p></td><td align="left"><p>Ca ATPase (calcium ATPase)</p></td><td align="left"><p>ATP2A2</p></td><td align="left"><p>2</p></td><td align="left"><p>3.97</p></td><td align="left"><p>3.81E−02</p></td></tr><tr><td align="left"><p>7</p></td><td align="left"><p>CYP_2E1 (cytochrome P450 2E1)</p></td><td align="left"><p>CYP2E1</p></td><td align="left"><p>5</p></td><td align="left"><p>3.74</p></td><td align="left"><p>4.36E−04</p></td></tr><tr><td align="left"><p>8</p></td><td align="left"><p>CYP_2E (cytochrome P450 family 2E)</p></td><td align="left"><p>CYP2E1</p></td><td align="left"><p>5</p></td><td align="left"><p>3.74</p></td><td align="left"><p>4.57E−04</p></td></tr><tr><td align="left"><p>9</p></td><td align="left"><p>GLY (glycine receptor)</p></td><td align="left"><p>GLRA1</p></td><td align="left"><p>3</p></td><td align="left"><p>3.74</p></td><td align="left"><p>1.02E−02</p></td></tr><tr><td align="left"><p>10</p></td><td align="left"><p>CYP_1B1 (cytochrome P450 1B1)</p></td><td align="left"><p>CYP1B1</p></td><td align="left"><p>3</p></td><td align="left"><p>3.70</p></td><td align="left"><p>1.03E−02</p></td></tr><tr><td align="left"><p>11</p></td><td align="left"><p>CYP_1B (cytochrome P450 family 1B)</p></td><td align="left"><p>CYP1B1</p></td><td align="left"><p>3</p></td><td align="left"><p>3.70</p></td><td align="left"><p>1.06E−02</p></td></tr></tbody></table></table-wrap></p>
            </sec>
            <sec id="Sec14">
              <title>CCA (Compound Cluster Analysis)</title>
              <p id="Par40">Certain properties of a compound set may be evident only in structurally similar subgroups. CCA allows identification of enriched features in structurally similar clusters of compounds. In CSgator, we obtained three compound clusters (CC #1–#3) in the 40 input compounds by setting the number of clusters, k = 3. Then, a network of CCs and disease classes is generated (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). This network showed the distribution of their original indications, and several notable connections were observed. CC #2 was linked to several diseases including <italic>viral infectious disease</italic>. There are several studies that herpes virus-triggered immune response drives lymphangiogenesis [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. Both CC #2 and #3 were strongly connected to cancer, which may be expected because inhibition of lymphangiogenesis has emerged as a promising strategy for cancer therapy [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR50">50</xref>].<fig id="Fig2"><label>Fig. 2</label><caption xml:lang="en"><p>CCA result for the anti-lymphangiogenetic screening hits. CC #1–#3 are the structurally similar clusters of the input compounds generated by k-means clustering (k = 3), which are linked to the relevant DO (Disease Ontology) terms</p></caption><graphic specific-use="HTML" mime-subtype="PNG" xlink:href="MediaObjects/13321_2019_339_Fig2_HTML.png" /></fig></p>
            </sec>
          </sec>
        </sec>
        <sec id="Sec15" sec-type="conclusions">
          <title>Conclusions</title>
          <p id="Par41">CSgator is a highly comprehensive and integrated analytic system for compound set analysis in terms of targets, bioactivity profiles, structural properties, and disease indications. Such information is crucial to interpret a set of compounds such as high-throughput screening hits, avoid potential side effects or toxicity, and investigate polypharmacology profiles for drug discovery and development. It provides unique functions such as CSEA and CCA, which are not available in other similar tools and databases. It showed that CSgator can give novel clues on drug mode-of-action and the underlying targets for phenotypic screening hits, as shown in the example case of interpreting the anti-lymphangiogenesis screening hits.</p>
        </sec>
      </body>
      <back>
        <ack>
          <title>Authors’ contributions</title>
          <sec>
            <p>WK designed the study, and SP, YK, HJ, SJ, HL collected data and performed the analysis, and SP implemented the web site. SP and WK wrote the manuscript. All authors read and approved the final manuscript.</p>
          </sec>
          <sec id="FPar1">
            <title>Acknowledgements</title>
            <p id="Par42">We thank Seungmin Kang for helpful discussions and comments.</p>
          </sec>
          <sec id="FPar2">
            <title>Competing interests</title>
            <p id="Par43">The authors declare that they have no competing interests.</p>
          </sec>
          <sec id="FPar3">
            <title>Availability and data and materials</title>
            <p id="Par44">The web platform can be accessible at <ext-link xlink:href="http://csgator.ewha.ac.kr" ext-link-type="uri">http://csgator.ewha.ac.kr</ext-link>.</p>
          </sec>
          <sec id="FPar4">
            <title>Funding</title>
            <p id="Par45">This work was funded by Grants from National Research Foundation of Korea (NRF-2017R1A2B4007855, and NRF-2017M3C9A5028690) and from Institution for Information and communications Technology Promotion(IITP) (No. 2016-0-00289).</p>
          </sec>
          <sec id="FPar5">
            <title>Publisher’s Note</title>
            <p id="Par46">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
          </sec>
        </ack>
        <ref-list id="Bib1">
          <title>References</title>
          <ref-list>
            <ref id="CR1">
              <label>1.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Bleicher</surname>
                    <given-names>KH</given-names>
                  </name>
                  <name>
                    <surname>Böhm</surname>
                    <given-names>H-J</given-names>
                  </name>
                  <name>
                    <surname>Müller</surname>
                    <given-names>K</given-names>
                  </name>
                  <name>
                    <surname>Alanine</surname>
                    <given-names>AI</given-names>
                  </name>
                </person-group>
                <article-title xml:lang="en">Hit and lead generation: beyond high-throughput screening</article-title>
                <source>Nat Rev Drug Discov</source>
                <year>2003</year>
                <volume>2</volume>
                <fpage>369</fpage>
                <lpage>378</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD3sXjslamtb8%3D</pub-id>
                <pub-id pub-id-type="doi">10.1038/nrd1086</pub-id>
                <pub-id pub-id-type="pmid">12750740</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR2">
              <label>2.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Macarron</surname>
                    <given-names>R</given-names>
                  </name>
                  <name>
                    <surname>Banks</surname>
                    <given-names>MN</given-names>
                  </name>
                  <name>
                    <surname>Bojanic</surname>
                    <given-names>D</given-names>
                  </name>
                  <etal />
                </person-group>
                <article-title xml:lang="en">Impact of high-throughput screening in biomedical research</article-title>
                <source>Nat Rev Drug Discov</source>
                <year>2011</year>
                <volume>10</volume>
                <fpage>188</fpage>
                <lpage>195</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC3MXisFensbY%3D</pub-id>
                <pub-id pub-id-type="doi">10.1038/nrd3368</pub-id>
                <pub-id pub-id-type="pmid">21358738</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR3">
              <label>3.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Antolin</surname>
                    <given-names>A</given-names>
                  </name>
                  <name>
                    <surname>Workman</surname>
                    <given-names>P</given-names>
                  </name>
                  <name>
                    <surname>Mestres</surname>
                    <given-names>J</given-names>
                  </name>
                  <name>
                    <surname>Al-Lazikani</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <article-title xml:lang="en">Polypharmacology in precision oncology: current applications and future prospects</article-title>
                <source>Curr Pharm Des</source>
                <year>2017</year>
                <volume>22</volume>
                <fpage>6935</fpage>
                <lpage>6945</lpage>
                <pub-id pub-id-type="doi">10.2174/1381612822666160923115828</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR4">
              <label>4.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Chen</surname>
                    <given-names>X</given-names>
                  </name>
                  <name>
                    <surname>Ji</surname>
                    <given-names>ZL</given-names>
                  </name>
                  <name>
                    <surname>Chen</surname>
                    <given-names>YZ</given-names>
                  </name>
                </person-group>
                <article-title xml:lang="en">TTD: therapeutic target database</article-title>
                <source>Nucleic Acids Res</source>
                <year>2002</year>
                <volume>30</volume>
                <fpage>412</fpage>
                <lpage>415</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD38Xht12rtrw%3D</pub-id>
                <pub-id pub-id-type="doi">10.1093/nar/30.1.412</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR5">
              <label>5.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Degtyarenko</surname>
                    <given-names>K</given-names>
                  </name>
                  <name>
                    <surname>de Matos</surname>
                    <given-names>P</given-names>
                  </name>
                  <name>
                    <surname>Ennis</surname>
                    <given-names>M</given-names>
                  </name>
                  <etal />
                </person-group>
                <article-title xml:lang="en">ChEBI: a database and ontology for chemical entities of biological interest</article-title>
                <source>Nucleic Acids Res</source>
                <year>2008</year>
                <volume>36</volume>
                <fpage>D344</fpage>
                <lpage>D350</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD1cXhtVWju7c%3D</pub-id>
                <pub-id pub-id-type="doi">10.1093/nar/gkm791</pub-id>
                <pub-id pub-id-type="pmid">17932057</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR6">
              <label>6.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Gunther</surname>
                    <given-names>S</given-names>
                  </name>
                  <name>
                    <surname>Kuhn</surname>
                    <given-names>M</given-names>
                  </name>
                  <name>
                    <surname>Dunkel</surname>
                    <given-names>M</given-names>
                  </name>
                  <etal />
                </person-group>
                <article-title xml:lang="en">SuperTarget and Matador: resources for exploring drug-target relationships</article-title>
                <source>Nucleic Acids Res</source>
                <year>2007</year>
                <volume>36</volume>
                <fpage>D919</fpage>
                <lpage>D922</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD1cXhtVWis7s%3D</pub-id>
                <pub-id pub-id-type="doi">10.1093/nar/gkm862</pub-id>
                <pub-id pub-id-type="pmid">17942422</pub-id>
                <pub-id pub-id-type="pmcid">2238858</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR7">
              <label>7.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Law</surname>
                    <given-names>V</given-names>
                  </name>
                  <name>
                    <surname>Knox</surname>
                    <given-names>C</given-names>
                  </name>
                  <name>
                    <surname>Djoumbou</surname>
                    <given-names>Y</given-names>
                  </name>
                  <etal />
                </person-group>
                <article-title xml:lang="en">DrugBank 4.0: shedding new light on drug metabolism</article-title>
                <source>Nucleic Acids Res</source>
                <year>2014</year>
                <volume>42</volume>
                <fpage>D1091</fpage>
                <lpage>D1097</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC2cXos1Kh</pub-id>
                <pub-id pub-id-type="doi">10.1093/nar/gkt1068</pub-id>
                <pub-id pub-id-type="pmid">24203711</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR8">
              <label>8.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Sharman</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name>
                    <surname>Benson</surname>
                    <given-names>HE</given-names>
                  </name>
                  <name>
                    <surname>Pawson</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <etal />
                </person-group>
                <article-title xml:lang="en">IUPHAR-DB: updated database content and new features</article-title>
                <source>Nucleic Acids Res</source>
                <year>2013</year>
                <volume>41</volume>
                <fpage>D1083</fpage>
                <lpage>D1088</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC38XhvV2ktr3M</pub-id>
                <pub-id pub-id-type="doi">10.1093/nar/gks960</pub-id>
                <pub-id pub-id-type="pmid">23087376</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR9">
              <label>9.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Wang</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name>
                    <surname>Suzek</surname>
                    <given-names>T</given-names>
                  </name>
                  <name>
                    <surname>Zhang</surname>
                    <given-names>J</given-names>
                  </name>
                  <etal />
                </person-group>
                <article-title xml:lang="en">PubChem BioAssay: 2014 update</article-title>
                <source>Nucleic Acids Res</source>
                <year>2014</year>
                <volume>42</volume>
                <fpage>D1075</fpage>
                <lpage>D1082</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC2cXoslaq</pub-id>
                <pub-id pub-id-type="doi">10.1093/nar/gkt978</pub-id>
                <pub-id pub-id-type="pmid">24198245</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR10">
              <label>10.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Bento</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name>
                    <surname>Gaulton</surname>
                    <given-names>A</given-names>
                  </name>
                  <name>
                    <surname>Hersey</surname>
                    <given-names>A</given-names>
                  </name>
                  <etal />
                </person-group>
                <article-title xml:lang="en">The ChEMBL bioactivity database: an update</article-title>
                <source>Nucleic Acids Res</source>
                <year>2014</year>
                <volume>42</volume>
                <fpage>D1083</fpage>
                <lpage>D1090</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC2cXoslWl</pub-id>
                <pub-id pub-id-type="doi">10.1093/nar/gkt1031</pub-id>
                <pub-id pub-id-type="pmid">24214965</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR11">
              <label>11.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Irwin</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name>
                    <surname>Sterling</surname>
                    <given-names>T</given-names>
                  </name>
                  <name>
                    <surname>Mysinger</surname>
                    <given-names>MM</given-names>
                  </name>
                  <etal />
                </person-group>
                <article-title xml:lang="en">ZINC: a free tool to discover chemistry for biology</article-title>
                <source>J Chem Inf Model</source>
                <year>2012</year>
                <volume>52</volume>
                <fpage>1757</fpage>
                <lpage>1768</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC38XmvFGnsrg%3D</pub-id>
                <pub-id pub-id-type="doi">10.1021/ci3001277</pub-id>
                <pub-id pub-id-type="pmid">22587354</pub-id>
                <pub-id pub-id-type="pmcid">3402020</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR12">
              <label>12.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Roider</surname>
                    <given-names>HG</given-names>
                  </name>
                  <name>
                    <surname>Pavlova</surname>
                    <given-names>N</given-names>
                  </name>
                  <name>
                    <surname>Kirov</surname>
                    <given-names>I</given-names>
                  </name>
                  <etal />
                </person-group>
                <article-title xml:lang="en">Drug2Gene: an exhaustive resource to explore effectively the drug-target relation network</article-title>
                <source>BMC Bioinformatics</source>
                <year>2014</year>
                <volume>15</volume>
                <fpage>68</fpage>
                <pub-id pub-id-type="doi">10.1186/1471-2105-15-68</pub-id>
                <pub-id pub-id-type="pmid">24618344</pub-id>
                <pub-id pub-id-type="pmcid">4234465</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR13">
              <label>13.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Cheng</surname>
                    <given-names>T</given-names>
                  </name>
                  <name>
                    <surname>Li</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name>
                    <surname>Wang</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name>
                    <surname>Bryant</surname>
                    <given-names>SH</given-names>
                  </name>
                </person-group>
                <article-title xml:lang="en">Identifying compound-target associations by combining bioactivity profile similarity search and public databases mining</article-title>
                <source>J Chem Inf Model</source>
                <year>2011</year>
                <volume>51</volume>
                <fpage>2440</fpage>
                <lpage>2448</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC3MXhtValsb3N</pub-id>
                <pub-id pub-id-type="doi">10.1021/ci200192v</pub-id>
                <pub-id pub-id-type="pmid">21834535</pub-id>
                <pub-id pub-id-type="pmcid">3180241</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR14">
              <label>14.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Helal</surname>
                    <given-names>KY</given-names>
                  </name>
                  <name>
                    <surname>Maciejewski</surname>
                    <given-names>M</given-names>
                  </name>
                  <name>
                    <surname>Gregori-Puigjané</surname>
                    <given-names>E</given-names>
                  </name>
                  <etal />
                </person-group>
                <article-title xml:lang="en">Public domain HTS fingerprints: design and evaluation of compound bioactivity profiles from PubChem’s bioassay repository</article-title>
                <source>J Chem Inf Model</source>
                <year>2016</year>
                <volume>56</volume>
                <fpage>390</fpage>
                <lpage>398</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC28XhtVGnsrg%3D</pub-id>
                <pub-id pub-id-type="doi">10.1021/acs.jcim.5b00498</pub-id>
                <pub-id pub-id-type="pmid">26898267</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR15">
              <label>15.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>William</surname>
                    <given-names>T</given-names>
                  </name>
                  <name>
                    <surname>Backman</surname>
                    <given-names>H</given-names>
                  </name>
                  <name>
                    <surname>Girke</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <article-title xml:lang="en">bioassayR: cross-target analysis of small molecule bioactivity</article-title>
                <source>J Chem Inf Model</source>
                <year>2016</year>
                <volume>9</volume>
                <fpage>99</fpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC28XhtV2it7%2FI</pub-id>
                <pub-id pub-id-type="doi">10.1021/acs.jcim.6b00109</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR16">
              <label>16.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Kim</surname>
                    <given-names>S</given-names>
                  </name>
                  <name>
                    <surname>Thiessen</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name>
                    <surname>Bolton</surname>
                    <given-names>EE</given-names>
                  </name>
                  <etal />
                </person-group>
                <article-title xml:lang="en">PubChem substance and compound databases</article-title>
                <source>Nucleic Acids Res</source>
                <year>2016</year>
                <volume>44</volume>
                <fpage>D1202</fpage>
                <lpage>D1213</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC2sXhtV2gu7bE</pub-id>
                <pub-id pub-id-type="doi">10.1093/nar/gkv951</pub-id>
                <pub-id pub-id-type="pmid">26400175</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR17">
              <label>17.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>O’Boyle</surname>
                    <given-names>NM</given-names>
                  </name>
                  <name>
                    <surname>Banck</surname>
                    <given-names>M</given-names>
                  </name>
                  <name>
                    <surname>James</surname>
                    <given-names>CA</given-names>
                  </name>
                  <etal />
                </person-group>
                <article-title xml:lang="en">Open Babel: an open chemical toolbox</article-title>
                <source>J Cheminform</source>
                <year>2011</year>
                <volume>3</volume>
                <fpage>33</fpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC3MXhsVWjurbF</pub-id>
                <pub-id pub-id-type="doi">10.1186/1758-2946-3-33</pub-id>
                <pub-id pub-id-type="pmid">21982300</pub-id>
                <pub-id pub-id-type="pmcid">3198950</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR18">
              <label>18.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Magrane</surname>
                    <given-names>M</given-names>
                  </name>
                  <collab>UniProt Consortium</collab>
                </person-group>
                <article-title xml:lang="en">UniProt Knowledgebase: a hub of integrated protein data</article-title>
                <source>Database (Oxford)</source>
                <year>2011</year>
                <volume>2011</volume>
                <fpage>bar009</fpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC3MXltlKjsLc%3D</pub-id>
                <pub-id pub-id-type="doi">10.1093/database/bar009</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR19">
              <label>19.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Maglott</surname>
                    <given-names>D</given-names>
                  </name>
                  <name>
                    <surname>Ostell</surname>
                    <given-names>J</given-names>
                  </name>
                  <name>
                    <surname>Pruitt</surname>
                    <given-names>KD</given-names>
                  </name>
                  <name>
                    <surname>Tatusova</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <article-title xml:lang="en">Entrez gene: gene-centered information at NCBI</article-title>
                <source>Nucleic Acids Res</source>
                <year>2011</year>
                <volume>39</volume>
                <fpage>D52</fpage>
                <lpage>D57</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC3sXivF2ltbc%3D</pub-id>
                <pub-id pub-id-type="doi">10.1093/nar/gkq1237</pub-id>
                <pub-id pub-id-type="pmid">21115458</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR20">
              <label>20.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Liu</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name>
                    <surname>Wei</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name>
                    <surname>Yu</surname>
                    <given-names>G</given-names>
                  </name>
                  <etal />
                </person-group>
                <article-title xml:lang="en">DCDB 2.0: a major update of the drug combination database</article-title>
                <source>Database (Oxford)</source>
                <year>2014</year>
                <volume>2014</volume>
                <fpage>bau124</fpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC2MXhvVGkt7c%3D</pub-id>
                <pub-id pub-id-type="doi">10.1093/database/bau124</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR21">
              <label>21.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Davis</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name>
                    <surname>Grondin</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name>
                    <surname>Johnson</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <etal />
                </person-group>
                <article-title xml:lang="en">The Comparative Toxicogenomics Database: update 2017</article-title>
                <source>Nucleic Acids Res</source>
                <year>2017</year>
                <volume>45</volume>
                <fpage>D972</fpage>
                <lpage>D978</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC1cXhsVKrurg%3D</pub-id>
                <pub-id pub-id-type="doi">10.1093/nar/gkw838</pub-id>
                <pub-id pub-id-type="pmid">27651457</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR22">
              <label>22.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Gilson</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name>
                    <surname>Liu</surname>
                    <given-names>T</given-names>
                  </name>
                  <name>
                    <surname>Baitaluk</surname>
                    <given-names>M</given-names>
                  </name>
                  <etal />
                </person-group>
                <article-title xml:lang="en">BindingDB in 2015: a public database for medicinal chemistry, computational chemistry and systems pharmacology</article-title>
                <source>Nucleic Acids Res</source>
                <year>2016</year>
                <volume>44</volume>
                <fpage>D1045</fpage>
                <lpage>D1053</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC2sXhtV2gu7fM</pub-id>
                <pub-id pub-id-type="doi">10.1093/nar/gkv1072</pub-id>
                <pub-id pub-id-type="pmid">26481362</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR23">
              <label>23.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Benson</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name>
                    <surname>Smith</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name>
                    <surname>Khazanov</surname>
                    <given-names>NA</given-names>
                  </name>
                  <etal />
                </person-group>
                <article-title xml:lang="en">Binding MOAD, a high-quality protein-ligand database</article-title>
                <source>Nucleic Acids Res</source>
                <year>2008</year>
                <volume>36</volume>
                <fpage>D674</fpage>
                <lpage>D678</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD1cXhtVSrsr8%3D</pub-id>
                <pub-id pub-id-type="doi">10.1093/nar/gkm911</pub-id>
                <pub-id pub-id-type="pmid">18055497</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR24">
              <label>24.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Wagner</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name>
                    <surname>Coffman</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name>
                    <surname>Ainscough</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <etal />
                </person-group>
                <article-title xml:lang="en">DGIdb 2.0: mining clinically relevant drug-gene interactions</article-title>
                <source>Nucleic Acids Res</source>
                <year>2016</year>
                <volume>44</volume>
                <fpage>D1036</fpage>
                <lpage>D1044</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC2sXhtV2gu7nL</pub-id>
                <pub-id pub-id-type="doi">10.1093/nar/gkv1165</pub-id>
                <pub-id pub-id-type="pmid">26531824</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR25">
              <label>25.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Chan</surname>
                    <given-names>WKB</given-names>
                  </name>
                  <name>
                    <surname>Zhang</surname>
                    <given-names>H</given-names>
                  </name>
                  <name>
                    <surname>Yang</surname>
                    <given-names>J</given-names>
                  </name>
                  <etal />
                </person-group>
                <article-title xml:lang="en">GLASS: a comprehensive database for experimentally validated GPCR-ligand associations</article-title>
                <source>Bioinformatics</source>
                <year>2015</year>
                <volume>31</volume>
                <fpage>3035</fpage>
                <lpage>3042</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC28Xhs1GisLvM</pub-id>
                <pub-id pub-id-type="doi">10.1093/bioinformatics/btv302</pub-id>
                <pub-id pub-id-type="pmid">25971743</pub-id>
                <pub-id pub-id-type="pmcid">4668776</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR26">
              <label>26.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Szklarczyk</surname>
                    <given-names>D</given-names>
                  </name>
                  <name>
                    <surname>Santos</surname>
                    <given-names>A</given-names>
                  </name>
                  <name>
                    <surname>von Mering</surname>
                    <given-names>C</given-names>
                  </name>
                  <etal />
                </person-group>
                <article-title xml:lang="en">STITCH 5: augmenting protein–chemical interaction networks with tissue and affinity data</article-title>
                <source>Nucleic Acids Res</source>
                <year>2016</year>
                <volume>44</volume>
                <fpage>D380</fpage>
                <lpage>D384</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC2sXhtV2nsrnE</pub-id>
                <pub-id pub-id-type="doi">10.1093/nar/gkv1277</pub-id>
                <pub-id pub-id-type="pmid">26590256</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR27">
              <label>27.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Thorn</surname>
                    <given-names>CF</given-names>
                  </name>
                  <name>
                    <surname>Klein</surname>
                    <given-names>TE</given-names>
                  </name>
                  <name>
                    <surname>Altman</surname>
                    <given-names>RB</given-names>
                  </name>
                </person-group>
                <article-title xml:lang="en">PharmGKB: the pharmacogenomics knowledge base</article-title>
                <source>Methods Mol Biol</source>
                <year>2013</year>
                <volume>1015</volume>
                <fpage>311</fpage>
                <lpage>320</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC3sXhslaku77O</pub-id>
                <pub-id pub-id-type="doi">10.1007/978-1-62703-435-7_20</pub-id>
                <pub-id pub-id-type="pmid">23824865</pub-id>
                <pub-id pub-id-type="pmcid">4084821</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR28">
              <label>28.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Kanehisa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name>
                    <surname>Furumichi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name>
                    <surname>Tanabe</surname>
                    <given-names>M</given-names>
                  </name>
                  <etal />
                </person-group>
                <article-title xml:lang="en">KEGG: new perspectives on genomes, pathways, diseases and drugs</article-title>
                <source>Nucleic Acids Res</source>
                <year>2017</year>
                <volume>45</volume>
                <fpage>D353</fpage>
                <lpage>D361</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC1cXhslWgsrw%3D</pub-id>
                <pub-id pub-id-type="doi">10.1093/nar/gkw1092</pub-id>
                <pub-id pub-id-type="pmid">27899662</pub-id>
                <pub-id pub-id-type="pmcid">27899662</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR29">
              <label>29.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Roth</surname>
                    <given-names>BL</given-names>
                  </name>
                  <name>
                    <surname>Lopez</surname>
                    <given-names>E</given-names>
                  </name>
                  <name>
                    <surname>Patel</surname>
                    <given-names>S</given-names>
                  </name>
                  <name>
                    <surname>Kroeze</surname>
                    <given-names>WK</given-names>
                  </name>
                </person-group>
                <article-title xml:lang="en">The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrassment of riches?</article-title>
                <source>The Neuroscientist</source>
                <year>2000</year>
                <volume>6</volume>
                <fpage>252</fpage>
                <lpage>262</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD3cXlvVyhsr8%3D</pub-id>
                <pub-id pub-id-type="doi">10.1177/107385840000600408</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR30">
              <label>30.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <collab>Gene Ontology Consortium</collab>
                </person-group>
                <article-title xml:lang="en">Gene ontology consortium: going forward</article-title>
                <source>Nucleic Acids Res</source>
                <year>2015</year>
                <volume>43</volume>
                <fpage>D1049</fpage>
                <lpage>D1056</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC2sXhtVymtLvE</pub-id>
                <pub-id pub-id-type="doi">10.1093/nar/gku1179</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR31">
              <label>31.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Schriml</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name>
                    <surname>Arze</surname>
                    <given-names>C</given-names>
                  </name>
                  <name>
                    <surname>Nadendla</surname>
                    <given-names>S</given-names>
                  </name>
                  <etal />
                </person-group>
                <article-title xml:lang="en">Disease ontology: a backbone for disease semantic integration</article-title>
                <source>Nucleic Acids Res</source>
                <year>2012</year>
                <volume>40</volume>
                <fpage>D940</fpage>
                <lpage>D946</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC3MXhs12hur7O</pub-id>
                <pub-id pub-id-type="doi">10.1093/nar/gkr972</pub-id>
                <pub-id pub-id-type="pmid">22080554</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR32">
              <label>32.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Erwin</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name>
                    <surname>Perkins</surname>
                    <given-names>WJ</given-names>
                  </name>
                </person-group>
                <article-title xml:lang="en">Medline: a guide to effective searching in PubMed &amp;amp; other interfaces, 2nd Edition</article-title>
                <source>Anesthesiology</source>
                <year>2007</year>
                <volume>107</volume>
                <fpage>360</fpage>
                <lpage>361</lpage>
                <pub-id pub-id-type="doi">10.1097/01.anes.0000271865.33903.be</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR33">
              <label>33.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Bickerton</surname>
                    <given-names>GR</given-names>
                  </name>
                  <name>
                    <surname>Paolini</surname>
                    <given-names>GV</given-names>
                  </name>
                  <name>
                    <surname>Besnard</surname>
                    <given-names>J</given-names>
                  </name>
                  <etal />
                </person-group>
                <article-title xml:lang="en">Quantifying the chemical beauty of drugs</article-title>
                <source>Nat Chem</source>
                <year>2012</year>
                <volume>4</volume>
                <fpage>90</fpage>
                <lpage>98</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC38Xht1aktLk%3D</pub-id>
                <pub-id pub-id-type="doi">10.1038/nchem.1243</pub-id>
                <pub-id pub-id-type="pmid">22270643</pub-id>
                <pub-id pub-id-type="pmcid">3524573</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR34">
              <label>34.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Subramanian</surname>
                    <given-names>A</given-names>
                  </name>
                  <name>
                    <surname>Tamayo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name>
                    <surname>Mootha</surname>
                    <given-names>VK</given-names>
                  </name>
                  <etal />
                </person-group>
                <article-title xml:lang="en">Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title>
                <source>Proc Natl Acad Sci USA</source>
                <year>2005</year>
                <volume>102</volume>
                <fpage>15545</fpage>
                <lpage>15550</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD2MXht1ShtrnO</pub-id>
                <pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR35">
              <label>35.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Varin</surname>
                    <given-names>T</given-names>
                  </name>
                  <name>
                    <surname>Gubler</surname>
                    <given-names>H</given-names>
                  </name>
                  <name>
                    <surname>Parker</surname>
                    <given-names>CN</given-names>
                  </name>
                  <name>
                    <surname>Zhang</surname>
                    <given-names>J-H</given-names>
                  </name>
                  <name>
                    <surname>Raman</surname>
                    <given-names>P</given-names>
                  </name>
                  <name>
                    <surname>Ertl</surname>
                    <given-names>P</given-names>
                  </name>
                  <name>
                    <surname>Schuffenhauer</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title xml:lang="en">Compound set enrichment: a novel approach to analysis of primary HTS data</article-title>
                <source>J Chem Inf Model</source>
                <year>2010</year>
                <volume>50</volume>
                <fpage>2067</fpage>
                <lpage>2078</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC3cXhsVWhsbbN</pub-id>
                <pub-id pub-id-type="doi">10.1021/ci100203e</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR36">
              <label>36.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Martin</surname>
                    <given-names>YC</given-names>
                  </name>
                  <name>
                    <surname>Kofron</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name>
                    <surname>Traphagen</surname>
                    <given-names>LM</given-names>
                  </name>
                </person-group>
                <article-title xml:lang="en">Do structurally similar molecules have similar biological activity?</article-title>
                <source>J Med Chem</source>
                <year>2002</year>
                <pub-id pub-id-type="doi">10.1021/JM020155C</pub-id>
                <pub-id pub-id-type="pmid">12408721</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR37">
              <label>37.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Schulz</surname>
                    <given-names>MMP</given-names>
                  </name>
                  <name>
                    <surname>Reisen</surname>
                    <given-names>F</given-names>
                  </name>
                  <name>
                    <surname>Zgraggen</surname>
                    <given-names>S</given-names>
                  </name>
                  <etal />
                </person-group>
                <article-title xml:lang="en">Phenotype-based high-content chemical library screening identifies statins as inhibitors of in vivo lymphangiogenesis</article-title>
                <source>Proc Natl Acad Sci USA</source>
                <year>2012</year>
                <volume>109</volume>
                <fpage>E2665</fpage>
                <lpage>E2674</lpage>
                <pub-id pub-id-type="doi">10.1073/pnas.1206036109</pub-id>
                <pub-id pub-id-type="pmid">22949700</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR38">
              <label>38.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Albig</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name>
                    <surname>Schiemann</surname>
                    <given-names>WP</given-names>
                  </name>
                </person-group>
                <article-title xml:lang="en">Identification and characterization of regulator of G protein signaling 4 (RGS4) as a novel inhibitor of tubulogenesis: RGS4 inhibits mitogen-activated protein kinases and vascular endothelial growth factor signaling</article-title>
                <source>Mol Biol Cell</source>
                <year>2005</year>
                <volume>16</volume>
                <fpage>609</fpage>
                <lpage>625</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD2MXhtVGitL0%3D</pub-id>
                <pub-id pub-id-type="doi">10.1091/mbc.e04-06-0479</pub-id>
                <pub-id pub-id-type="pmid">15548600</pub-id>
                <pub-id pub-id-type="pmcid">545898</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR39">
              <label>39.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Aguilar</surname>
                    <given-names>B</given-names>
                  </name>
                  <name>
                    <surname>Choi</surname>
                    <given-names>I</given-names>
                  </name>
                  <name>
                    <surname>Choi</surname>
                    <given-names>D</given-names>
                  </name>
                  <etal />
                </person-group>
                <article-title xml:lang="en">Lymphatic reprogramming by Kaposi sarcoma herpes virus promotes the oncogenic activity of the virus-encoded G-protein-coupled receptor</article-title>
                <source>Cancer Res</source>
                <year>2012</year>
                <volume>72</volume>
                <fpage>5833</fpage>
                <lpage>5842</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC38Xhs1ynt7fJ</pub-id>
                <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-1229</pub-id>
                <pub-id pub-id-type="pmid">22942256</pub-id>
                <pub-id pub-id-type="pmcid">3500425</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR40">
              <label>40.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Chen</surname>
                    <given-names>H</given-names>
                  </name>
                  <name>
                    <surname>Guan</surname>
                    <given-names>R</given-names>
                  </name>
                  <name>
                    <surname>Lei</surname>
                    <given-names>Y</given-names>
                  </name>
                  <etal />
                </person-group>
                <article-title xml:lang="en">Lymphangiogenesis in gastric cancer regulated through Akt/mTOR-VEGF-C/VEGF-D axis</article-title>
                <source>BMC Cancer</source>
                <year>2015</year>
                <volume>15</volume>
                <fpage>103</fpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC2MXmvVWrurY%3D</pub-id>
                <pub-id pub-id-type="doi">10.1186/s12885-015-1109-0</pub-id>
                <pub-id pub-id-type="pmid">25884175</pub-id>
                <pub-id pub-id-type="pmcid">4358729</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR41">
              <label>41.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Ekshyyan</surname>
                    <given-names>O</given-names>
                  </name>
                  <name>
                    <surname>Moore-Medlin</surname>
                    <given-names>TN</given-names>
                  </name>
                  <name>
                    <surname>Raley</surname>
                    <given-names>MC</given-names>
                  </name>
                  <etal />
                </person-group>
                <article-title xml:lang="en">Anti-lymphangiogenic properties of mTOR inhibitors in head and neck squamous cell carcinoma experimental models</article-title>
                <source>BMC Cancer</source>
                <year>2013</year>
                <volume>13</volume>
                <fpage>320</fpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC3sXht1WjsL3I</pub-id>
                <pub-id pub-id-type="doi">10.1186/1471-2407-13-320</pub-id>
                <pub-id pub-id-type="pmid">23815869</pub-id>
                <pub-id pub-id-type="pmcid">3702388</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR42">
              <label>42.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Bertozzi</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name>
                    <surname>Hess</surname>
                    <given-names>PR</given-names>
                  </name>
                  <name>
                    <surname>Kahn</surname>
                    <given-names>ML</given-names>
                  </name>
                </person-group>
                <article-title xml:lang="en">Platelets: covert regulators of lymphatic development</article-title>
                <source>Arterioscler Thromb Vasc Biol</source>
                <year>2010</year>
                <volume>30</volume>
                <fpage>2368</fpage>
                <lpage>2371</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC3cXhsVCksb%2FO</pub-id>
                <pub-id pub-id-type="doi">10.1161/ATVBAHA.110.217281</pub-id>
                <pub-id pub-id-type="pmid">21071706</pub-id>
                <pub-id pub-id-type="pmcid">2994722</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR43">
              <label>43.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Schoppmann</surname>
                    <given-names>SF</given-names>
                  </name>
                  <name>
                    <surname>Alidzanovic</surname>
                    <given-names>L</given-names>
                  </name>
                  <name>
                    <surname>Schultheis</surname>
                    <given-names>A</given-names>
                  </name>
                  <etal />
                </person-group>
                <article-title xml:lang="en">Thrombocytes correlate with lymphangiogenesis in human esophageal cancer and mediate growth of lymphatic endothelial cells in vitro</article-title>
                <source>PLoS ONE</source>
                <year>2013</year>
                <volume>8</volume>
                <fpage>e66941</fpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC3sXhtFSjsrnO</pub-id>
                <pub-id pub-id-type="doi">10.1371/journal.pone.0066941</pub-id>
                <pub-id pub-id-type="pmid">23840559</pub-id>
                <pub-id pub-id-type="pmcid">3694157</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR44">
              <label>44.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Hong</surname>
                    <given-names>H</given-names>
                  </name>
                  <name>
                    <surname>Jiang</surname>
                    <given-names>L</given-names>
                  </name>
                  <name>
                    <surname>Lin</surname>
                    <given-names>Y</given-names>
                  </name>
                  <etal />
                </person-group>
                <article-title xml:lang="en">TNF-alpha promotes lymphangiogenesis and lymphatic metastasis of gallbladder cancer through the ERK1/2/AP-1/VEGF-D pathway</article-title>
                <source>BMC Cancer</source>
                <year>2016</year>
                <volume>16</volume>
                <fpage>240</fpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC2sXisVKitro%3D</pub-id>
                <pub-id pub-id-type="doi">10.1186/s12885-016-2259-4</pub-id>
                <pub-id pub-id-type="pmid">26992854</pub-id>
                <pub-id pub-id-type="pmcid">4799527</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR45">
              <label>45.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Lin</surname>
                    <given-names>W</given-names>
                  </name>
                  <name>
                    <surname>Jiang</surname>
                    <given-names>L</given-names>
                  </name>
                  <name>
                    <surname>Chen</surname>
                    <given-names>Y</given-names>
                  </name>
                  <etal />
                </person-group>
                <article-title xml:lang="en">Vascular endothelial growth factor-D promotes growth, lymphangiogenesis and lymphatic metastasis in gallbladder cancer</article-title>
                <source>Cancer Lett</source>
                <year>2012</year>
                <volume>314</volume>
                <fpage>127</fpage>
                <lpage>136</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC3MXhsFehu7nP</pub-id>
                <pub-id pub-id-type="doi">10.1016/j.canlet.2011.09.004</pub-id>
                <pub-id pub-id-type="pmid">22071224</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR46">
              <label>46.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Jordan-Williams</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name>
                    <surname>Ramanujam</surname>
                    <given-names>N</given-names>
                  </name>
                  <name>
                    <surname>Farr</surname>
                    <given-names>AG</given-names>
                  </name>
                  <name>
                    <surname>Ruddell</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title xml:lang="en">The lymphatic endothelial mCLCA1 antibody induces proliferation and growth of lymph node lymphatic sinuses</article-title>
                <source>PLoS ONE</source>
                <year>2016</year>
                <volume>11</volume>
                <fpage>e0156079</fpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC28XhsFSqsLnN</pub-id>
                <pub-id pub-id-type="doi">10.1371/journal.pone.0156079</pub-id>
                <pub-id pub-id-type="pmid">27224029</pub-id>
                <pub-id pub-id-type="pmcid">4880189</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR47">
              <label>47.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Stacker</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name>
                    <surname>Achen</surname>
                    <given-names>MG</given-names>
                  </name>
                </person-group>
                <article-title xml:lang="en">From anti-angiogenesis to anti-lymphangiogenesis: emerging trends in cancer therapy</article-title>
                <source>Lymphat Res Biol</source>
                <year>2008</year>
                <volume>6</volume>
                <fpage>165</fpage>
                <lpage>172</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD1cXhsFajsbjN</pub-id>
                <pub-id pub-id-type="doi">10.1089/lrb.2008.1015</pub-id>
                <pub-id pub-id-type="pmid">19093789</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR48">
              <label>48.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Sessa</surname>
                    <given-names>R</given-names>
                  </name>
                  <name>
                    <surname>Chen</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <article-title xml:lang="en">Lymphangiogenesis: a new player in herpes simplex virus 1-triggered T-cell response</article-title>
                <source>Immunol Cell Biol</source>
                <year>2017</year>
                <volume>95</volume>
                <fpage>5</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC2sXjs1Cg</pub-id>
                <pub-id pub-id-type="doi">10.1038/icb.2016.108</pub-id>
                <pub-id pub-id-type="pmid">28044065</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR49">
              <label>49.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Wuest</surname>
                    <given-names>TR</given-names>
                  </name>
                  <name>
                    <surname>Carr</surname>
                    <given-names>DJJ</given-names>
                  </name>
                </person-group>
                <article-title xml:lang="en">VEGF-A expression by HSV-1-infected cells drives corneal lymphangiogenesis</article-title>
                <source>J Exp Med</source>
                <year>2010</year>
                <volume>207</volume>
                <fpage>101</fpage>
                <lpage>115</lpage>
                <pub-id pub-id-type="doi">10.1084/jem.20091385</pub-id>
                <pub-id pub-id-type="pmid">20026662</pub-id>
                <pub-id pub-id-type="pmcid">2812544</pub-id>
              </mixed-citation>
            </ref>
            <ref id="CR50">
              <label>50.</label>
              <mixed-citation publication-type="journal">
                <person-group person-group-type="author">
                  <name>
                    <surname>Nisato</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name>
                    <surname>Tille</surname>
                    <given-names>J-C</given-names>
                  </name>
                  <name>
                    <surname>Pepper</surname>
                    <given-names>MS</given-names>
                  </name>
                </person-group>
                <article-title xml:lang="en">Lymphangiogenesis and tumor metastasis</article-title>
                <source>Thromb Haemost</source>
                <year>2003</year>
                <volume>90</volume>
                <fpage>591</fpage>
                <lpage>597</lpage>
                <pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD3sXot1ynu70%3D</pub-id>
                <pub-id pub-id-type="doi">10.1160/TH03-04-0206</pub-id>
                <pub-id pub-id-type="pmid">14515178</pub-id>
              </mixed-citation>
            </ref>
          </ref-list>
        </ref-list>
        <glossary>
          <title>Abbreviations</title>
          <def-list>
            <def-item>
              <term>CSEA</term>
              <def>
                <p id="Par2">Compound Set Enrichment Analysis</p>
              </def>
            </def-item>
            <def-item>
              <term>CC</term>
              <def>
                <p id="Par3">Compound Cluster</p>
              </def>
            </def-item>
            <def-item>
              <term>CCA</term>
              <def>
                <p id="Par4">Compound Cluster Analysis</p>
              </def>
            </def-item>
            <def-item>
              <term>HEA</term>
              <def>
                <p id="Par5">Hit Enriched Assay</p>
              </def>
            </def-item>
            <def-item>
              <term>ES</term>
              <def>
                <p id="Par6">enrichment score</p>
              </def>
            </def-item>
            <def-item>
              <term>LLR</term>
              <def>
                <p id="Par7">log likelihood ratio</p>
              </def>
            </def-item>
            <def-item>
              <term>OR</term>
              <def>
                <p id="Par8">odds ratio</p>
              </def>
            </def-item>
            <def-item>
              <term>MDS</term>
              <def>
                <p id="Par9">multidimensional scaling</p>
              </def>
            </def-item>
            <def-item>
              <term>HTS</term>
              <def>
                <p id="Par10">high-throughput screening</p>
              </def>
            </def-item>
            <def-item>
              <term>SAR</term>
              <def>
                <p id="Par11">structure–activity relation</p>
              </def>
            </def-item>
            <def-item>
              <term>InChI</term>
              <def>
                <p id="Par12">International Chemical Identifier</p>
              </def>
            </def-item>
            <def-item>
              <term>ID</term>
              <def>
                <p id="Par13">identification</p>
              </def>
            </def-item>
            <def-item>
              <term>DB</term>
              <def>
                <p id="Par14">database</p>
              </def>
            </def-item>
            <def-item>
              <term>CTD</term>
              <def>
                <p id="Par15">Comparative Toxicogenomics Database</p>
              </def>
            </def-item>
            <def-item>
              <term>MeSH</term>
              <def>
                <p id="Par16">Medical Subject Headings</p>
              </def>
            </def-item>
            <def-item>
              <term>NIH</term>
              <def>
                <p id="Par17">National Institutes of Health</p>
              </def>
            </def-item>
            <def-item>
              <term>NCGC</term>
              <def>
                <p id="Par18">NCATS Chemical Genomics Center</p>
              </def>
            </def-item>
            <def-item>
              <term>QED</term>
              <def>
                <p id="Par19">quantitative estimation of drug-likeness</p>
              </def>
            </def-item>
            <def-item>
              <term>logP</term>
              <def>
                <p id="Par20">partition coefficient</p>
              </def>
            </def-item>
            <def-item>
              <term>Tc</term>
              <def>
                <p id="Par21">Tanimoto coefficient</p>
              </def>
            </def-item>
            <def-item>
              <term>GO</term>
              <def>
                <p id="Par22">gene ontology</p>
              </def>
            </def-item>
            <def-item>
              <term>DO</term>
              <def>
                <p id="Par23">Disease Ontology</p>
              </def>
            </def-item>
            <def-item>
              <term>CAS</term>
              <def>
                <p id="Par24">Chemical Abstracts Service</p>
              </def>
            </def-item>
            <def-item>
              <term>qHTS</term>
              <def>
                <p id="Par25">quantitative high-throughput screening</p>
              </def>
            </def-item>
          </def-list>
        </glossary>
      </back>
    </article>
